Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 10Recurrence 2Neoplasms, Plasma Cell 1Immunoglobulin Light-chain Amyloidosis 1Amyloidosis 1

Interventions

daratumumab 6Dexamethasone 6pomalidomide 4Bortezomib 4Focal Adhesion Protein-Tyrosine Kinases 3venetoclax 2Specimen Handling 2Cyclophosphamide 2Calcium Dobesilate 2talquetamab 1ixazomib 1idecabtagene vicleucel 1dexamethasone acetate 1dexamethasone 21-phosphate 1darlin protein, Dictyostelium 1belantamab mafodotin 1auricularum 1X-Rays 1Tissue Banks 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Polymerase Chain Reaction 1Pharmaceutical Preparations 1Phantoms, Imaging 1Melphalan 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1Biopsy 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Immunoglobulin Light-chain Amyloidosis × belantamab mafodotin × Clear all
NCT05145816 2026-05-07

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

University of Texas Southwestern Medical Center

Phase 1/2 Recruiting
37 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡